The medication is commonly used for symptomatic relief for symptoms related to physical discomfort associated with the spasm of smooth muscles within internal organs and blood vessels. This approach generally aligns with the established clinical applications for anticholinergic agents.

Relief for Acute Visceral Spasm and Colic

The medication is commonly used across therapeutic domains involving symptoms that create noticeable physiological strain in the digestive, biliary, and urinary tracts. This is considered relevant for managing symptom clusters that may become intense or disruptive, such as the painful manifestations of intestinal colic, renal (kidney) colic, and episodes of biliary colic. It is relevant for easing painful cramping and internal tension that define these acute crises, which contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Colicky Pain This medication is commonly used in scenarios where additional symptomatic assistance is required to address acute, spasmodic pain in the internal organs.

Addressing Symptoms from Internal Tension and Constriction

Платифиллин is applied in clinical settings marked by the sudden tightening of various smooth muscle groups, playing a role in managing symptoms that create noticeable physiological strain. This is generally used to help with symptoms stemming from significant internal tension in the gastrointestinal system, as well as symptoms caused by the spasm of cerebral or peripheral blood vessels. It contributes to maintaining functional stability and easing the overall symptom burden of these disruptive manifestations, particularly when such spasms create noticeable interference with routine activities.

“The focus of its use is generally to support the patient during difficult episodes by easing distress caused by visceral and vascular spasm.”

The medication is commonly used across conditions presenting with acute episodes, including various forms of colic, symptomatic spasms of the urinary tract, and symptomatic manifestations of cerebral and peripheral vessel constriction.

Regulatory References

1. National Institutes of Health (NIH) resources on Anticholinergic Medications

Who Can and Cannot Use Platyphylline (Платифиллин) — Official Regulatory Information

Official regulatory guidelines strictly define the populations eligible to use Platyphylline hydrotartrate, classifying non-eligibility into absolute contraindications and conditional restrictions.

Contraindicated Populations (Absolute Exclusion)

The medicine is contraindicated and must not be used in patients with specific pre-existing conditions, including glaucoma, Myasthenia Gravis, paralytic intestinal obstruction, severe hypertension, and acute heart failure. Absolute exclusion also applies to patients with hepatic failure or renal failure, and those with known hypersensitivity to the drug's components. Platyphylline is also formally contraindicated during both pregnancy and lactation (breastfeeding).

Restricted and Age-Based Eligibility

Use is subject to conditional restriction (use with caution) in the entire pediatric population. Specific caution is required for individuals with arrhythmias or tachycardia, Fever, Hyperthyroidism, and those with certain neurological conditions like Head Trauma or Down’s Syndrome. For intravenous administration, the medicine is contraindicated in children under 14 years of age. Use is established for the general Adult Population without listed contraindications.

Interactions with other medicines and products

Official regulatory information for Platyphylline hydrotartrate primarily documents pharmacodynamic interactions, which result in an additive effect when co-administered with certain substance classes.

---

Documented Interaction Patterns

Interaction Type	Interacting Agents / Classes	Officially Documented Outcome
Potentiation (Anticholinergic)	Other M-Cholinoblockers, Tricyclic Antidepressants, some Antihistamines, Phenothiazines	Increased risk of peripheral anticholinergic symptoms (e.g., dry mouth, urinary retention).
Potentiation (CNS)	CNS Depressants, Sedatives, Tranquilizers, Alcohol	Enhanced sedative effect and increased risk of Central Nervous System (CNS) depression.
Cardiotoxic Risk	MAO Inhibitors (MAOIs), certain Antiarrhythmics (e.g., Quinidine)	Increased risk of cardiotoxic effects, including tachycardia and cardiac rhythm disturbances.

---

Restrictions and Population Notes

The official labeling notes that alcohol consumption is not compatible with this medicine due to the confirmed potentiation of CNS depressant effects. No medicinal products are explicitly classified as absolutely contraindicated based on interaction risk alone, and there are no mandatory time separation rules for co-administration detailed in the primary regulatory texts.

Population-Specific Note: Regulatory documents indicate that elderly patients may have increased sensitivity and a greater potential for adverse effects due to the additive anticholinergic effects when co-administered with other interacting agents.

Receptor-Mediated Anticholinergic Action

Platyphylline exerts its primary mechanism of action by functioning as a competitive antagonist of muscarinic acetylcholine receptors (m-cholinoceptors). This interaction occurs postsynaptically, modulating pathways associated with the parasympathetic nervous system. By blocking the binding of the endogenous neurotransmitter acetylcholine, Platyphylline initiates a molecular cascade that decreases cholinergic signaling and modulates downstream physiological activity.

---

Modulation of Smooth Muscle Tone and Secretion

This antagonistic effect on m-cholinoceptors results in the reduction of muscle tone in various involuntary muscles, particularly within the gastrointestinal, urinary, and bronchial systems. Furthermore, the modification of signaling sequences in the eye and glandular tissue reduces secretory activity (salivary, bronchial, sweat glands) and alters the contractile state of the iris sphincter muscle, leading to mydriasis.

---

Direct Myotropic Effect

Independent of its anticholinergic activity, the compound also displays a direct spasmolytic action on smooth muscle cells. This secondary mechanism contributes to the compound's overall effect on muscle contractile activity across multiple organ systems.

Official Administration Guidelines

Administration of Platyphylline hydrotartrate is defined by the official pharmaceutical forms, which include tablets for oral use and a solution for parenteral administration.

Component	Official Instruction / Regimen
Route of Administration	Primarily Oral (for tablets) and Parenteral (most commonly Subcutaneous or, in certain contexts, Intravenous) for the solution.
Dosing Schedule	Subcutaneous: 2 mg to 4 mg per administration. Oral: 5 mg per tablet per administration. The maximum single subcutaneous dose is 10 mg, with a maximum daily limit of 30 mg.
Frequency and Timing	Generally administered 2 to 3 times per day for both the oral and injectable forms. Oral tablets are typically taken irrespective of food.
Age-Group Rules	Usage is generally recommended for individuals over 15 years of age. Caution is advised in older adults due to potential sensitivity, which may require lower dosing.
Special Conditions	The solution for injection must be clear and particle-free. Intravenous use requires slow administration and medical supervision. The total course of treatment is often defined as 10 to 20 days.

These official instructions establish a precise protocol by defining the two approved delivery methods (oral and injection) and their exact dose ranges, which must not exceed regulatory limits. This structure ensures that administration strictly adheres to the specified pharmaceutical forms and numerical parameters, providing a standardized framework for its use.

Research evidence / Overview of studies for Платифиллин

Foundational Research and Evidence for Acute Spasm and Colic

The research into Platyphylline hydrotartrate was studied for conditions characterized by acute or disruptive episodes, particularly those involving smooth muscle spasms in internal organs, such as intestinal, renal, and biliary colic. The evidence base largely comprises foundational pharmacological studies and older clinical observations. Foundational research examined the drug's activity on isolated tissue to monitor physiological strain or stress, and provided data on the compound's activity in laboratory models.

These older studies explored short-term symptom changes used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort. Findings describe patterns observed in the studies and contribute to understanding how patients reported their experience during periods of increased symptom activity. The available documentation reports short-term changes measured during the study period that were acute and short-lived.

Long-Term Evidence and Follow-Up Duration

Studies that have been observed in clinical settings primarily focus on episodes where symptoms become more noticeable, meaning the follow-up durations were limited. The duration of observation often corresponds to the immediate event, and evidence is limited regarding outcomes beyond this short timeframe.

The long-term effects are not fully established. Research exploring sustained patterns of change of the compound for conditions characterized by recurring symptoms is currently limited. Data are still emerging for uses that require extended-duration monitoring, and there is limited information for long-term outcomes or the durability of effect.

Studies in Specific Patient Groups

Evidence for Platyphylline primarily describes research involving adult populations who experience acute spasmodic events. Studies that were evaluated in special populations, such as children, older adults, or individuals with specific comorbidities, are limited or not consistently indexed in major systematic reviews.

Data for certain groups remain insufficient, meaning that subgroup findings are uncertain. The available results apply mainly to the populations studied, and evidence does not provide guidance on individual outcomes.

The Current Research Landscape and Key Uncertainties

When evaluated against contemporary international evidence standards, the overall certainty remains low. The primary research limitation is the absence of modern, definitive, placebo-controlled Randomized Controlled Trials (RCTs) that meet current international standards for assessing clinical outcomes.

Research was observed in some studies that primarily rely on older, observational data and foundational pharmacological principles. Comparative evidence is lacking. The evidence describes the available information—and what is still uncertain—about this compound, and studies contribute to the broader evidence landscape, but research provides context but not individual predictions.

Key Studies & References

1. Anticholinergic Medications - StatPearls - NCBI Bookshelf - NIH
2. Anticholinergic Agents - LiverTox - NCBI Bookshelf - NIH

Common questions about Платифиллин (FAQ)

---

Q: Is Платифиллин the same as other spasmolytics I've heard of?

A: Official product information classifies Platyphylline as both an anticholinergic agent and a spasmolytic, meaning its primary role is to relax smooth muscles. While it belongs to the same pharmacological class as drugs like atropine, regulatory texts often note that Platyphylline has its own distinct spectrum of effects.

Q: What are the most common side effects people report with Платифиллин?

A: The official product information lists documented adverse effects such as dry mouth, thirst, accommodation disorder (difficulty focusing your eyes), headache, and tachycardia (a faster than normal heart rate). Official labeling notes that the likelihood of experiencing these reactions is generally highest when the medicine is used in high doses.

Q: Is it normal to feel dizzy or have blurred vision after getting a Платифиллин shot?

A: Dizziness and accommodation disorder (blurred vision) are listed as documented effects on the nervous system and eye, respectively, in the official safety profile. These effects are associated with the drug's anticholinergic mechanism of action. If a patient experiences any concerning effects, they should seek guidance from a healthcare professional.

Q: Can elderly patients safely use Платифиллин?

A: Official administration guidelines generally recommend use for individuals over 15 years old. Caution is advised for older adults due to potential increased sensitivity. Any decisions regarding its use or dosage adjustments must be determined by a healthcare professional.

Q: Does Платифиллин interact with antidepressants or anxiety medication?

A: Regulatory documents state that co-administration with other M-Cholinoblockers, Tricyclic Antidepressants, and certain tranquilizers can increase the risk of peripheral anticholinergic symptoms (like dry mouth or urinary retention). It may also enhance the sedative effect of CNS depressants.

Q: Is it safe to drive after receiving a Платифиллин injection?

A: The official safety profile includes side effects such as dizziness, headache, and impaired vision (accommodation disorder or paralysis). Because these effects can potentially impact attention and reaction time, official guidance advises caution regarding activities that require full alertness, such as driving or operating machinery.

Q: Is it normal for urination to feel slightly different after taking Платифиллин?

A: Platyphylline’s mechanism of action includes relaxing smooth muscle tone, which includes those in the urinary system. The effect on the urinary tract is consistent with the drug's pharmacological activity.

Q: What is the difference between Платифиллин and atropine?

A: Both substances are classified as anticholinergic agents, meaning they work by blocking certain nerve impulses. However, official pharmacological texts often note that Platyphylline possesses a distinct spectrum of effects compared to Atropine, implying differences in their specific actions on the body.

Q: Are there any clinical studies supporting the use of Платифиллин for stomach cramps?

A: Foundational research supports the drug's use for acute spasmodic events. Official indications specifically mention intestinal, renal, and biliary colic, confirming its therapeutic role for spasms of the internal organs.

Q: Can Платифиллин be used to treat spasms in the urinary tract?

A: Yes, regulatory information confirms the drug’s use for conditions involving urinary tract spasms, such as renal colic. This is consistent with its mechanism of action, which includes the reduction of smooth muscle tone within the urinary system.

Q: Why might a doctor prescribe Платифиллин for pain related to ulcers?

A: Official indications have historically included conditions like peptic ulcer. The drug's anticholinergic action may assist by relaxing smooth muscle spasm and decreasing the secretion of gastric and pancreatic fluids that can potentially worsen ulcer symptoms.

Q: Why do some people feel a temporary rush or palpitation after the injection?

A: Tachycardia (an increase in heart rate) is a documented cardiac side effect of Platyphylline, which is listed in the official safety information.

Q: Can children be given Платифиллин for spasms or pain?

A: Use of Platyphylline is subject to restrictions and caution across the entire pediatric population. Intravenous administration is contraindicated in children under 14 years of age, and specific caution is noted for young children with chronic lung diseases.

Q: Are there any long-term side effects associated with Платифиллин use?

A: Official research documentation indicates that evidence is limited regarding outcomes beyond the short timeframe of acute use. Therefore, long-term effects are not fully established in the current body of research.

Q: Does the efficacy of Платифиллин decrease over time with repeated use?

A: Research evidence primarily focuses on the drug's effect during acute events. Data on the durability of the effect with repeated use are limited, and regulatory texts do not confirm whether efficacy decreases over time.

Q: What recent research has been done on new uses for Платифиллин?

A: The research base largely consists of foundational pharmacological studies and older clinical observations. A primary limitation noted is the absence of modern, definitive, placebo-controlled trials, indicating limited widely recognized recent studies on new uses.

Q: Is Платифиллин used to treat colic in infants (high-level question only)?

A: The drug is formally contraindicated during lactation (breastfeeding). Furthermore, official guidance requires caution for all young children, especially those with chronic lung diseases.

Q: What are the signs of a serious, but rare, side effect from Платифиллин?

A: Specific serious adverse reactions listed in the regulatory label include anaphylactic reactions (severe allergic reaction), pulmonary atelectasis (lung collapse), and central nervous system effects such as acute psychosis or convulsions/seizures, particularly when used in high doses.

How to Store and Dispose of Платифиллин

Official regulatory documents define specific, mandatory conditions for the storage and disposal of Platyphylline, which must be followed to maintain the product's stability and ensure safety.

Storage Requirements

Storage Factor	Official Regulatory Specification
Maximum Temperature	Must not exceed 25 C (77 F).
Light Protection	Must be stored in a dark place.
Child Safety	Must be kept out of the reach and sight of children.

Disposal and Handling

Handling/Disposal Factor	Official Regulatory Specification
Handling	Requires protection from light to prevent product degradation.
Disposal	Disposal of unused product or waste material must be in accordance with local requirements.

These constraints establish that the medicine must be shielded from excessive heat and light throughout its shelf-life, and access by children is strictly prohibited by regulatory mandate. Expired or unused portions must be discarded according to the pharmaceutical waste protocols defined by local authorities.